• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

I Can’t Help Wondering How My Multiple Myeloma Came to Be

by | Apr 3, 2024 | Uncategorized

Source: CureToday articles Of everything I’ve ever done, I wonder how my multiple myeloma came to be. Read More

March is Myeloma Awareness Month

by | Mar 21, 2024 | Uncategorized

Source: CureToday articles Post Content Read More

The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease

by | Mar 20, 2024 | Uncategorized

Nat Commun. 2024 Mar 19;15(1):2458. doi: 10.1038/s41467-024-46594-0. ABSTRACT Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic...

FDA panel supports earlier use of two CAR-Ts for multiple myeloma

by | Mar 18, 2024 | Uncategorized

An FDA advisory committee voted that a pair of chimeric antigen receptor T-cell therapies should be approved for earlier line treatments in adults with relapsed or refractory multiple myeloma, although one produced far more deliberation.The committee determined the...

The Impact of Immunotherapy on Multiple Myeloma

by | Mar 14, 2024 | Uncategorized

Source: CureToday articles Here is a run-down of some topics we covered in the Spring 2024 issue of CURE. Read More

Taking Control of Diet May Improve Outcomes for Multiple Myeloma

by | Mar 13, 2024 | Uncategorized

Source: CureToday articles Eating a plant-based diet has been associated with sustained MRD negativity for patients with multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
  • Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis
  • What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?
  • Depression, anxiety prevalent among adults with lymphoma, multiple myeloma
  • Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
  • Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
  • Quadruplet Regimen Preferable to Triplets in Multiple Myeloma
  • Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
  • Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
  • Daratumumab regimen improves survival in transplant-ineligible multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT